Friday afternoon, the company and its partner Genmab shared word that the phase 3 Epcore DLBCL-1 trial missed on its primary ...

Exelixis may only have one drug on the market right now, but with phase 3 results for a potential new blockbuster on the ...

AbbVie struck a big deal to enter the hot PD-1xVEGF bispecific space. | In this week's Asia news recap, AbbVie struck a big ...

New York's attorney general has filed an insider trading lawsuit against former Emergent BioSolutions CEO Robert Kramer, ...

In 2023, Teva made a pledge to bolster its innovative medicines portfolio without leaving behind its century-long legacy as a ...

While Fujifilm has deep roots in the life sciences industry through its history working with X-ray film and diagnostic ...

In early 2025, the FDA was rocked by sweeping layoffs and leadership turnover, raising questions about whether the agency ...

Both Skyrizi and its cousin Rinvoq have landed in the annual top three, in varying positions, since 2022. That was once again the case in 2025, when Skyrizi retained its place at the top and Rinvoq ...

Xtandi, Astellas’ roughly $6 billion prostate cancer juggernaut by annual sales, is set to lose U.S. patent protection in ...

The FDA has told the makers of six flu vaccines that they need to add a notification to the label of their shots, warning of ...

This time, Tecvayli excelled as a solo agent, reducing the risk of disease progression or death by 71% over standard of care ...

The regulator’s Office of Prescription Drug Promotion (OPDP) has already sent out two letters alleging “false or misleading” ...